The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63)

Experimental Parasitology

Volumn 121, Issue 4, 2009, Pages 362-369

  Badiee, Ali ^a   Jaafari, Mahmoud R ^a   Khamesipour, Ali ^b   Samiei, Afshin ^a   Soroush, Dina ^a   Kheiri, Masoumeh Tavassoti ^c   Barkhordari, Farzaneh ^c   McMaster, W Robert ^d   Mahboudi, Fereidoun ^b  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c PASTEUR INSTITUTE OF IRAN   (Iran)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Adjuvant; Leishmaniasis; Liposome; Liposome charge; rgp63; Vaccine

Indexed keywords

CHOLESTEROL; DICETYL PHOSPHATE; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; DIPALMITOYLPHOSPHATIDYLCHOLINE; GAMMA INTERFERON; GLYCOPROTEIN; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 4; LEISHMANIA VACCINE; LIPOSOME; RECOMBINANT GLYCOPROTEIN GP 63; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BAGG ALBINO MOUSE; CONTROL GROUP; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENCAPSULATION; FEMALE; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; LEISHMANIA MAJOR; LEISHMANIASIS; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; DRUG CARRIERS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; IMMUNIZATION; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-4; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; LIPOSOMES; MEMBRANE GLYCOPROTEINS; MICE; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; SPLEEN; TH1 CELLS;

LEISHMANIA MAJOR; MUS;

EID: 61349113935     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2008.12.015     Document Type: Article

References (49)

1. Aebischer T., Wolfram M., Patzer S.I., Ilg T., Wiese M., and Overath P. Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants. Infection and Immunity 68 (2000) 1328-1336
2. Afrin F., and Ali N. Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes. Infection and Immunity 65 (1997) 2371-2377
3. Afrin F., Anam K., and Ali N. Induction of partial protection against Leishmania donovani by promastigote antigens in negatively charged liposomes. Journal of Parasitology 86 (2000) 730-735
4. Afrin F., Rajesh R., Anam K., Gopinath M., Pal S., and Ali N. Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice. Infection and Immunity 70 (2002) 6697-6706
5. Aramaki Y., Suda H., and Tsuchiya S. Interferon-gamma inductive effect of liposomes as an immunoadjuvant. Vaccine 13 (1995) 1809-1814
6. Badiee A., Jaafari M.R., and Khamesipour A. Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes. Experimental Parasitology 115 (2007) 127-134
7. Bhowmick S., Ravindran R., and Ali N. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response. Vaccine 25 (2007) 6544-6556
8. Bhowmick S., Ravindran R., and Ali N. Gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani. Infection and Immunity 76 (2008) 1003-1015
9. Bordier C. The promastigote surface protease of Leishmania. Parasitology Today 3 (1987) 151-153
10. Brandt L., Elhay M., Rosenkrands I., Lindblad E.B., and Andersen P. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infection and Immunity 68 (2000) 791-795
11. Campos-Neto A., Porrozzi R., Greeson K., Coler R.N., Webb J.R., Seiky Y.A., Reed S.G., and Grimaldi Jr. G. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infection and Immunity 69 (2001) 4103-4108
12. Coler R.N., and Reed S.G. Second-generation vaccines against leishmaniasis. Trends in Parasitology 21 (2005) 244-249
13. Copland M.J., Rades T., Davies N.M., and Baird M.A. Lipid based particulate formulations for the delivery of antigen. Immunology and Cell Biology 83 (2005) 97-105
14. Davidsen J., Rosenkrands I., Christensen D., Vangala A., Kirby D., Perrie Y., Agger E.M., and Andersen P. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6′-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochimica Biophysica Acta 1718 (2005) 22-31
15. Foged C., Arigita C., Sundblad A., Jiskoot W., Storm G., and Frokjaer S. Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine 22 (2004) 1903-1913
16. Frommel T.O., Button L.L., Fujikura Y., and McMaster W.R. The major surface glycoprotein (gp63) is present in both life stages of Leishmania. Molecular and Biochemical Parasitology 38 (1990) 25-32
17. Galdiero F., Carratelli C.R., Nuzzo I., Bentivoglio C., De Martino L., Gorga F., Folgore A., and Galdiero M. Beneficial effects of myristic, stearic or oleic acid as part of liposomes on experimental infection and antitumor effect in a murine model. Life Sciences 55 (1994) 499-509
18. Ghadiri, A., Rogozhkina, V., Mashko, R., McMaster, R.W., Mahboudi, F., 1998. High level expression of Leishmania major gp63 gene in different strains of E. coli under the control of lambda p1 Promoter. In: Monduzzi (Ed.), IX International Congress of Parasitology, Chiba, Japan, pp. 875-881.
19. Guy B., Pascal N., Francon A., Bonnin A., Gimenez S., Lafay-Vialon E., Trannoy E., and Haensler J. Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine. Vaccine 19 (2001) 1794-1805
20. Habibi G.R., Khamesipour A., McMaster W.R., and Mahboudi F. Cytokine gene expression in healing and non-healing cases of cutaneous leishmaniasis in response to in vitro stimulation with recombinant gp63 using semi-quantitative RT-PCR. Scandinavian Journal of Immunology 54 (2001) 414-420
21. Handman E., Button L.L., and McMaster W.R. Leishmania major: production of recombinant gp63, its antigenicity and immunogenicity in mice. Experimental Parasitology 70 (1990) 427-435
22. Hilgers L.A., and Snippe H. DDA as an immunological adjuvant. Research in Immunology 143 (1992) 494-503
23. Holten-Andersen L., Doherty T.M., Korsholm K.S., and Andersen P. Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infection and Immunity 72 (2004) 1608-1617
24. Jaafari M.R., Ghafarian A., Farrokh-Gisour A., Samiei A., Kheiri M.T., Mahboudi F., Barkhordari F., Khamesipour A., and McMaster W.R. Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice. Vaccine 24 (2006) 5708-5717
25. Jiao X., Wang R.Y., Feng Z., Alter H.J., and Shih J.W. Modulation of cellular immune response against hepatitis C virus nonstructural protein 3 by cationic liposome encapsulated DNA immunization. Hepatology 37 (2003) 452-460
26. Khamesipour A., Rafati S., Davoudi N., Maboudi F., and Modabber F. Leishmaniasis vaccine candidates for development: a global overview. Indian Journal of Medical Research 123 (2006) 423-438
27. Klinguer-Hamour C., Libon C., Plotnicky-Gilquin H., Bussat M.C., Revy L., Nguyen T., Bonnefoy J.Y., Corvaia N., and Beck A. DDA adjuvant induces a mixed Th1/Th2 immune response when associated with BBG2Na, a respiratory syncytial virus potential vaccine. Vaccine 20 (2002) 2743-2751
28. Kuwana M., Matsuura E., Kobayashi K., Okazaki Y., Kaburaki J., Ikeda Y., and Kawakami Y. Binding of beta 2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. Blood 105 (2005) 1552-1557
29. Larsen S.T., Hansen R., Hammer M., Tegner U., Poulsen O.M., and Nielsen G.D. Adjuvant effect of quaternary ammonium compounds in a murine model. Toxicology Letters 151 (2004) 389-398
30. Lee K.D., Pitas R.E., and Papahadjopoulos D. Evidence that the scavenger receptor is not involved in the uptake of negatively charged liposomes by cells. Biochimica Biophysica Acta 1111 (1992) 1-6
31. Lindblad E.B., Elhay M.J., Silva R., Appelberg R., and Andersen P. Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infection and Immunity 65 (1997) 623-629
32. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry 193 (1951) 265-275
33. Mazumdar T., Anam K., and Ali N. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice. Vaccine 22 (2004) 1162-1171
34. Mazumdar T., Anam K., and Ali N. Influence of phospholipid composition on the adjuvanticity and protective efficacy of liposome-encapsulated Leishmania donovani antigens. Journal of Parasitology 91 (2005) 269-274
35. Medina-Acosta E., Karess R.E., Schwartz H., and Russell D.G. The promastigote surface protease (gp63) of Leishmania is expressed but differentially processed and localized in the amastigote stage. Molecular and Biochemical Parasitology 37 (1989) 263-273
36. Nadim A., Javadian E., Tahvildar-Bidruni G., and Ghorbani M. Effectiveness of leishmanization in the control of cutaneous leishmaniasis. Bulletin de la Société de pathologie exotique et de ses filiales 76 (1983) 377-383
37. Nakanishi T., Kunisawa J., Hayashi A., Tsutsumi Y., Kubo K., Nakagawa S., Nakanishi M., Tanaka K., and Mayumi T. Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble proteins. Journal of Control Release 61 (1999) 233-240
38. Nishikawa K., Arai H., and Inoue K. Scavenger receptor-mediated uptake and metabolism of lipid vesicles containing acidic phospholipids by mouse peritoneal macrophages. Journal of Biological Chemistry 265 (1990) 5226-5231
39. O'Hagan D.T., and Singh M. Microparticles as vaccine adjuvants and delivery systems. Expert Review of Vaccines 2 (2003) 269-283
40. Olobo J.O., Anjili C.O., Gicheru M.M., Mbati P.A., Kariuki T.M., Githure J.I., Koech D.K., and McMaster W.R. Vaccination of vervet monkeys against cutaneous leishmaniosis using recombinant Leishmania 'major surface glycoprotein' (gp63). Veterinary Parasitology 60 (1995) 199-212
41. Reed S.G., and Scott P. T-cell and cytokine responses in leishmaniasis. Current Opinion in Immunology 5 (1993) 524-531
42. Reiner S.L., and Locksley R.M. The regulation of immunity to Leishmania major. Annual Review of Immunology 13 (1995) 151-177
43. Russell D.G., and Wilhelm H. The involvement of the major surface glycoprotein (gp63) of Leishmania promastigotes in attachment to macrophages. Journal of Immunology 136 (1986) 2613-2620
44. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. Journal of Immunology 126 (1981) 1614-1619
45. Taylor P.R., Martinez-Pomares L., Stacey M., Lin H.H., Brown G.D., and Gordon S. Macrophage receptors and immune recognition. Annual Review of Immunology 23 (2005) 901-944
46. Thiele L., Merkle H.P., and Walter E. Phagocytosis and phagosomal fate of surface-modified microparticles in dendritic cells and macrophages. Pharmaceutical Research 20 (2003) 221-228
47. Thiele L., Rothen-Rutishauser B., Jilek S., Wunderli-Allenspach H., Merkle H.P., and Walter E. Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages?. Journal of Control Release 76 (2001) 59-71
48. Titus R.G., Marchand M., Boon T., and Louis J.A. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunology 7 (1985) 545-555
49. Yotsumoto S., Aramaki Y., Kakiuchi T., and Tsuchiya S. Induction of antigen-dependent interleukin-12 production by negatively charged liposomes encapsulating antigens. Vaccine 22 (2004) 3503-3509